drugset / Trial / NCT04846231

Supplements, Placebo, or Rosuvastatin Study

NCT04846231

Phase 2 Completed 203 enrolled The Cleveland Clinic AstraZeneca · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A research study that is evaluating a low dose of an FDA approved statin medication in comparison to several commercially available over the counter dietary supplements which are marketed for cholesterol health. The study is comparing their effect on LDL cholesterol. LDL-cholesterol is low-density cholesterol and is sometimes referred to as "bad" cholesterol. Participants must live in Ohio and have a documented elevated LDL cholesterol level between 70-189mg/dL, must not currently be taking a statin or one of the dietary supplements included in the trial. Participants willing to discontinue a prohibited supplement for 4 weeks prior to enrollment will be allowed to participate. Trial participation is 4 weeks. Study medication will be provided at no charge. There will be 2 visits which include a lab draw at any Cleveland Clinic laboratory. Participants will be randomized (like a coin flip) to be in one of 8 possible groups: Rosuvastatin, Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice, or placebo. The study will enroll 200 participants.

Timeline

Start
2021-04-23
Primary completion
2022-07-19
Completion
2022-07-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosuvastatin Small molecule 5 mg

Indications